Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

NCT00622388 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large-Cell, Diffuse

Interventions

DRUG: Ofatumumab

Sponsor

GlaxoSmithKline